TITLE: Administration's FY2003 Budget Proposal for Prescription Drugs

CIS-NO: 2002-S361-22  
SOURCE: Committee on Finance. Senate  
DOC-TYPE: Hearing Retrieve the full text of testimony  
DOC-NO: S. Hrg. 107-430  
DATE: Mar. 7, 2002  
LENGTH: iv+138 p. il.  
CONG-SESS: 107-2  
ITEM-NO: 1038-A; 1038-B  
SUDOC: Y4.F49:S.HRG.107-430  
 
GPO-STOCK-NO: 552-070-28276-9.

SUMMARY:
Hearing to examine Administration Medicare reform proposals, focusing on proposal to establish an outpatient prescription drug benefit for Medicare beneficiaries.
 
Supplementary material (p. 63-138) includes witnesses' written statements and written replies to Committee questions, and submitted statements.

CONTENT-NOTATION: Medicare prescription drug benefit estab, Admin proposal

DESCRIPTORS:  
    MEDICARE; DRUGS; MEDICAL REGULATION; MANAGED HEALTH CARE

02-S361-22 TESTIMONY NO: 1     Mar. 7, 2002 p. 5-31
 
WITNESSES (and witness notations):
   SCULLY, THOMAS A. (Administrator, Centers for Medicare and Medicaid Services)
   JINDAL, BOBBY P. (Assistant Secretary, Planning and Evaluation, HHS)
 
STATEMENTS AND DISCUSSION:
   Overview of Administration prescription drug coverage proposal; views on Administration approach to strengthening Medicare program, including proposed prescription drug coverage.
 
CONTENT NOTATION:
   Medicare prescription drug benefit estab, Admin proposal
 
TESTIMONY DESCRIPTORS:
   DEPARTMENT OF HEALTH AND HUMAN SERVICES; GOVERNMENT EFFICIENCY; CENTERS FOR MEDICARE AND MEDICAID SERVICES
 
 
02-S361-22 TESTIMONY NO: 2     Mar. 7, 2002 p. 32-53, 63-98
 
WITNESSES (and witness notations):
   KERREY, BOB (President, New School University; representing Concord Coalition)
   CRIPPEN, DAN L. (Director, CBO)
 
STATEMENTS AND DISCUSSION:
   Opposition to adding Medicare prescription drug benefit without structural reform of Medicare program; overview of CBO projections of Medicare spending over 2003-2012 period, with comparison to Administration Medicare spending projections (related tables and graphs, p. 78-84, 90-94).
   Analysis of Medicare beneficiaries' projected spending for prescription drugs, with implications for costs of proposed prescription drug benefit; elaboration on Administration prescription drug benefit proposal and related issues.
 
CONTENT NOTATION:
   Medicare prescription drug benefit estab, Admin proposal
 
TESTIMONY DESCRIPTORS:
   CONCORD COALITION; CONGRESSIONAL BUDGET OFFICE; MEDICAL ECONOMICS; GOVERNMENT SPENDING; STATISTICAL DATA: HEALTH AND VITAL STATISTICS; PROJECTIONS
 
 
02-S361-22 TESTIMONY NO: 3     Mar. 7, 2002 p. 54-61, 103-121
 
WITNESSES (and witness notations):
   NOVELLI, WILLIAM D. (Executive Director and CEO, AARP)
   NEUMAN, PATRICIA (Director, Medicare Policy Project, Kaiser Family Foundation)
 
STATEMENTS AND DISCUSSION:
   Concerns regarding Administration Medicare prescription drug benefit proposal, with recommendations; assessment of Administration proposal for Medicare-endorsed prescription drug discount card program (related tables and graphs, p. 108-113).
 
CONTENT NOTATION:
   Medicare prescription drug benefit estab, Admin proposal
 
TESTIMONY DESCRIPTORS:
   KAISER, HENRY J., FAMILY FOUNDATION; AARP

LOAD-DATE: February 3, 2003